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Abstract
Background: Microglial activation plays an important role in neurodegenerative diseases through production of
nitric oxide (NO) and several pro-inflammatory cytokines. Lipoxins (LXs) and aspirin-triggered LXs (ATLs) are
considered to act as ‘braking signals’ in inflammation. In the present study, we investigated the effect of aspirin-
triggered LXA4 (ATL) on infiammatory responses induced by lipopolysaccharide (LPS) in murine microglial BV-2
cells.
Methods: BV-2 cells were treated with ATL prior to LPS exposure, and the effects of such treatment production of
nitric oxide (NO), inducible nitric oxide synthase (iNOS), interleukin-1b (IL-1b) and tumour necrosis factor-a (TNF-a)
were analysed by Griess reaction, ELISA, western blotting and quantitative RT-PCR. Moreover, we investigated the
effects of ATL on LPS-induced nuclear factor-B (NF-B) activation, phosphorylation of mitogen-activated protein
kinases (MAPKs) and activator protein-1 (AP-1) activation.
Results: ATL inhibited LPS-induced production of NO, IL-1b and TNF-a in a concentration-dependent manner.
mRNA expressions for iNOS, IL-1b and TNF-a in response to LPS were also decreased by ATL. These effects were
inhibited by Boc-2 (a LXA4 receptor antagonist). ATL significantly reduced nuclear translocation of NF-B p65,
degradation of the inhibitor IB-a, and phosphorylation of extracellular signal-regulated kinase (ERK) and p38
MAPK in BV-2 cells activated with LPS. Furthermore, the DNA binding activity of NF-B and AP-1 was blocked by
ATL.
Conclusions: This study indicates that ATL inhibits NO and pro-inflammatory cytokine production at least in part
via NF-B, ERK, p38 MAPK and AP-1 signaling pathways in LPS-activated microglia. Therefore, ATL may have
therapeutic potential for various neurodegenerative diseases.
Background
There is increasing awareness that inflammation may
play a role in various neurodegenerative disorders,
including Alzheimer’sd i s e a s e ,P a r k i n s o n ’sd i s e a s e ,H I V -
associated dementia, trauma, multiple sclerosis and
stroke [1,2]. Microglial cells are generally considered to
be the immune cells of the central nervous system
(CNS). They respond to neuronal injury or immunologic
challenges with a reaction termed microglial activation.
Activated microglial cells can serve diverse beneficial
functions essential to neuron survival, which include cel-
lular maintenance and innate immunity [3,4]. However,
overactivated microglia can induce significant and highly
detrimental neurotoxic effects through excess produc-
tion of a large array of cytotoxic factors such as super-
oxide, nitric oxide (NO), tumor necrosis factor-a (TNF-
a) and interleukin-1b (IL-1b) [1]. Overactivation of
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tors results in deleterious and progressive neurotoxic
consequences [5,6]. In several studies it has been shown
that reduction of pro-inflammatory mediators produced
by microglia may attenuate the severity of neuronal
damage [7]. Therefore, inhibiting inflammatory cytokine
production by activated microglia may be useful for pre-
venting neurodegeneration [8-10].
Lipoxins (LXs) are endogenous lipid mediators with
potent anti-infiammatory and pro-resolving actions [11].
Of special interest, aspirin can also trigger transcellular
biosynthesis of 15-epimers of LX, termed aspirin-trig-
gered LX (ATL) [12], that share the potent anti-infiam-
matory actions of LX but are more resistant to
metabolic inactivation [13]. LXs and ATL elicit multicel-
lular responses via a specific G protein-coupled receptor
termed the LXA4 receptor (ALX) that has been identi-
fied in human [14], mouse [15] and rat [16] tissues. In
our previous papers, we evaluated the anti-inflammatory
activity of an LXA4 analogue, 5(S), 6(R)-LXA4 methyl
ester, in a rat model of permanent focal cerebral ische-
mia and focal cerebral ischemia reperfusion [17,18]. Our
results showed that this LXA4 analogue could attenuate
focal ischemia-induced inflammatory responses and
inhibit activation of microglia in vivo.E x p r e s s i o no f
functional ALXs was identified in neural stem cells, neu-
rons, astrocytes and microglia [19-23]. Microglial cells
are key sensors and versatile effectors in normal and
pathologic brain [24]. These findings suggest that micro-
glia may be a target for LXs in brain. However, the
effects of LXs on expression of inflammation-related
genes and molecular mechanisms in microglia have not
been demonstrated.
Lipopolysaccharide (LPS), a component of the outer
membrane of Gram-negative bacteria, initiates a number
of major cellular responses that play critical roles in the
pathogenesis of inflammatory responses and has been
commonly used to model proinflammatory and neuro-
toxic activation of microglia [25,26]. We used LPS as a
stimulant of the microglial reactivity in the current
study.
In the present study, we investigated the impact of
ATL on the infiammatory response induced by LPS in
murine microglial BV-2 cells, as well as the signaling
pathways involved in these processes. Our data suggest
that ATL inhibits NO and pro-inflammatory cytokine
production in LPS-activated microglia at least in part via
NF-B, ERK, p38 MAPK and AP-1 signaling pathways.
Methods
Cell culture
The immortalized murine microglia cell line BV-2 was
purchased from Cell Resource Centre of Peking Union
Medical College (Beijing, China) and maintained in
Dulbecco’s modified Eagle’s medium with F12 supple-
ment (DMEM/F12, Gibco, Grand Island, NY) supple-
mented with 10% fetal bovine serum (Gibco), 100 U/ml
penicillin and 100 μg/ml streptomycin at 37°C in a
humidified atmosphere of 95% air, 5% CO2.C o n f i u e n t
cultures were passaged by trypsinization. BV-2 cells
were seeded onto 96-well plates (10
4 cells/well for cell
viability assay), 24-well-culture plates (10
5 cells/well for
ELISA and NO measurement, 10
4 cells/well for immu-
nofluorescence), 6-well plates (2.5 × 10
5 cells/well for
PCR) or 100 mm culture dishes (1.2 × 10
6 cells/dish for
western blotting and EMSA). Before each experiment,
cells were serum-starved for 12 h. BV-2 cells were incu-
bated in the initial experiments with different concentra-
tions (1 nM, 10 nM or 100 nM) of ATL (Cayman
Chemical, Ann Arbor, MI), leading to a concentration
of 100 nM ATL used in further experiments or vehicle
(0.035% ethanol) for 30 min before addition of 100 ng/
ml LPS (Escherichia coli O26:B6, Sigma-Aldrich, St.
Louis, MO) under serum-free conditions. To investigate
the involvement of ALXs in the anti-inflammatory
effects of ATL, the cells were treated with 100 μMB o c -
2 (Phoenix Pharmaceuticals), a specific receptor antago-
nist, prior to the treatment with ATL for 30 min.
RNA isolation, reverse-transcriptase (RT) PCR and real-
time PCR
Total RNA was extracted from BV-2 cells with TRIzol
reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’sp r o t o c o l .1 . 0μg of total RNA was sub-
jected to oligo-dT-primed RT with ReverTra Ace Kit
(Toyobo, Osaka, Japan).
Semi-quantitative PCR was carried out with DNA
polymerase (Toyobo) by using specific primers (Invitro-
gen): 5’-GGCAACTCTGTTGAGGAAAG-3’ and 5’-
GGCTCTCGGTAGACGAGA-3’, which amplify the 423
bp product for ALX1/FPR-rs1; and 5’-GTCAAGAT-
CAACAGAAGAAACC-3’ and 5’-GGGCTCTCTCAA-
GACTATAAGG-3’, which amplify 298 bp product for
ALX2/FPR2; and 5’-TGGAATCCTGTGGCATCCAT-
GAAAC-3’ and 5’-TAAAACGCAGCTCAGTAA-
CAGTCCG-3’, which amplify 349 bp product for b-
a c t i n .T h ea m p l i f i e dP C Rp r o d u c t sw e r er e s o l v e db y2 %
agarose gel electrophoresis.
Real-time PCR was performed for a quantitative analy-
sis of iNOS, IL-1b and TNF-a mRNA expression using
SYBR Green real-time PCR Master Mix (Toyobo) on an
MX3000P real-time PCR system (Stratagene). The fol-
lowing primers were used (Invitrogen): 5’-
CAGCTGGGCTGTACAAACCTT-3’ and 5’-C A T T G -
GAAGTGAAGCGTTTCG-3’, which amplify the 95 bp
product for iNOS; 5’-CAACCAACAAGTGATATTCTC-
CATG-3’ and 5’- GATCCACACTCTCCAGCTGCA-3’,
which amplify the 152 bp product for IL-1b;5 ’-
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TGGGAGTAGACAAGGTACAACCC-3’, which amplify
the 175 bp product for TNF-a;a n d5 ’-
TGTCCACCTTCCAGCAGATGT-3’ and 5’-AGCT-
CAGTAACAGTCCGCCTAGA-3’, which amplify the
101 bp product for b-actin. Relative gene expression was
calculated by the 2
-ΔΔCT method [27].
Cell viability assay
Cell viability was measured by quantitative colorimetric
assay with MTT (Sigma-Aldrich), showing the mito-
chondrial activity of living cells. BV-2 cells in 96-well
plates were pretreated with various concentrations of
ATL for 30 min and incubated with or without LPS for
24 h in the continued presence of ATL. Upon termina-
tion of the experiments, the culture media were aspi-
rated and MTT (0.5 mg/ml) was added to cells and then
incubated at 37°C for 4 h. The supernatant was aspi-
rated and dimethyl sulfoxide (Sigma-Aldrich) was added
to the wells. Insoluble crystals were dissolved by mixing
and the plates were read on an automated Tecan Sun-
rise absorbance reader, using a test wavelength of 570
nm and a reference wavelength of 630 nm.
Nitrite measurements
Production of NO was determined by measuring the
level of accumulated nitrite, a metabolite of NO in the
culture supernatant using Griess reagent (Sigma-
Aldrich). After 24 h of treatment with LPS with or with-
out ATL, the culture supernatants were collected and
mixed with an equal volume of Griess reagent in 96-
well culture plates and incubated at room temperature
for 10 min. The absorbance was measured at 540 nm
and nitrite concentrations were calculated by reference
to a standard curve generated by known concentrations
of sodium nitrite.
ELISA for IL-1b and TNF-a
BV-2 cells in 24-well plates were stimulated for 24 h,
and then culture supernatants were harvested. Levels of
IL-1b and TNF-a in 100 μl medium were measured by
commercial ELISA kits (Boster Biological Technology,
Wuhan, China) according to the manufacturer’s
instructions.
Immunofluorescence confocal microscopy
For the detection of intracellular location of NF-Bp 6 5 ,
BV-2 cells were cultured on sterile glass cover slips in
24 well plates and treated with ATL and LPS as
described above. At various times after the LPS treat-
ment, cells were fixed with 4% paraformaldehyde in PBS
and permeabilized with 0.1% Triton X-100 in PBS. After
rinsing, cells were blocked with 3% BSA in PBS for 1 h
and incubated with rabbit anti-NF-B p65 antibodies
(1:200, Santa Cruz Biotechnology, Santa Cruz) overnight
at 4°C. After washing, cells were incubated with FITC-
conjugated goat anti-rabbit IgG (1:400, Pierce, Rockford,
IL) for 1 h and counterstained with 4, 6-diamidino-2-
phenylindole (DAPI, Roche, Shanghai, China) for the
identification of nuclei. After washing with PBS, the
cover slips were mounted with antifade mounting med-
ium (Beyotime, China) on slides, and the cells were
observed with a confocal microscope Olympus Fluoview
FV500.
Protein extraction
For making whole cell lysates, the cells were lysed in
radioimmune precipitation assay (RIPA) buffer supple-
mented with protease inhibitor cocktail (Roche). Nuclear
and cytoplasmic fractionations were performed with
Proteo JET™ Cytoplasmic and Nuclear Protein Extrac-
tion Kit (Fermentas Life Science) according to manufac-
turer’s protocol.
Western blot analysis
Equal amounts of cytoplasmic, nuclear, or whole cell
extracts were electrophoresed on sodium dodecyl sul-
fate-polyacrylamide gels, and then transferred onto a
polyvinylidene difluoride membrane (Millipore). The
transformed membrane was blocked for 1 h and incu-
bated with indicated primary antibodies (Santa Cruz
Biotechnology) at 4°C overnight. The primary antibodies
usedwere as follows: rabbit anti-iNOS (1:500), b-actin
(1:1000), p65 (1:1000), Lamin B (1:1000), IB-a (1:500),
ERK1/2 (1:1000), p38 (1:1000), JNK (1:1000) and mouse
anti-phosphorylated ERK1/2, p38, JNK antibody
(1:1000). The membrane was washed three times with
Tris-bufffered saline containing 0.05% Tween 20 (TBST)
for 10 min and incubated with anti-rabbit or anti-mouse
IgG-horseradish peroxidase (1:5000, Pierce) at room
temperature for 1 h. The Supersignal West Pico chemi-
luminescent substrate system (Pierce) was used to detect
immunoreactive bands. The intensity of protein bands
after western blotting were quantitated by using Quan-
tity One Version 4.6.3 Image software (Bio-Rad) and
normalized against proper loading controls.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described above. Oli-
gonucleotides corresponding to the NF-B( 5 ’-AGTT-
GAGGGGACTTTCCCAGGC-3’)a n dA P - 1( 5 ’-
CGCTTGATGAGTCAGCCGGAA-3’) binding site con-
sensus sequences were synthesized and end-labeled with
biotin by Invitrogen. EMSAs were performed using the
LightShift chemiluminescent EMSA kit (Pierce). Briefly,
20 fmol of biotin-labeled, double strand probe was incu-
bated for 20 min at room temperature in 20 μlo f
EMSA binding buffer containing 2.5% glycerol, 5 mM
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6 μg of nuclear proteins. For competition EMSA, 200-
fold (4 pmol) excess unlabeled, double strand probe was
added to the binding reaction. The DNA-nuclear pro-
tein complexes were resolved by electrophoresis in 6%
nondenaturing polyacrylamide gel in 0.5 × Tris-borate-
E D T A( T B E )b u f f e ra t1 0 0V .Gels were then electro-
blotted onto Hybond nylon membranes (GE Healthcare)
at 380 mA for 50 min. The membranes were then
cross-linked for 15 min with the membrane face down
on a transilluminator at 312 nm, and the biotinylated
protein-DNA bands were detected with HRP-conjugated
streptavidin using the chemiluminescent nucleic acid
detection system (Pierce).
Statistical analysis
Data are expressed as means ± SEM of the indicated
number of independent experiments. Changes in IB
protein levels were analyzed by two-way ANOVA (treat-
ment and time). All other da t aw e r ea n a l y z e db yo n e -
way ANOVA. Least significant difference (LSD) post
hoc test was used for multiple comparisons. Statistical
analysis was performed using the SPSS software version
17.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was consid-
ered statistically significant.
Results
ALXs are expressed in BV-2 microglial cells
Using RT-PCR, we showed that both ALX1/FPR-rs1 and
ALX2/FPR2 were expressed in BV-2 microglial cells.
The mRNA expression levels of these two receptors
were significantly enhanced when the cells were exposed
to LPS (100 ng/ml) for 6 h (Figure 1).
ATL inhibits LPS-induced NO, IL-1b and TNF-a production
in BV-2 cells
Initially, we evaluated the effects of ATL on NO, IL-1b
and TNF-a production in LPS-stimulated BV-2 micro-
glia. BV-2 cells were incubated with vehicle or different
concentrations of ATL (1, 10 and 100 nM) for 30 min
and stimulated with 100 ng/ml LPS for 24 h. To deter-
mine NO production, we measured nitrite released into
the culture medium using the Griess reagent. Stimula-
tion of BV-2 cells with LPS markedly increased (about
7.5-fold) NO production, compared with that generated
under control conditions. Pretreatment with ATL signif-
icantly inhibited this increase in a concentration-depen-
dent manner (Figure 2A).
We then tested whether ATL reduces the production
of LPS-induced pro-inflammatory cytokines IL-1b and
TNF-a using ELISA. As shown in Figure 2B and 2C, sti-
mulation of BV-2 cells with LPS led to a significant
increase in the levels of IL-1b and TNF-a in the cell-
conditioned media after 24 h. Pretreatment of BV-2
cells with ATL significantly inhibited the LPS-induced
IL-1b and TNF-a production, concentration
dependently.
To evaluate the role of the ALXs in the anti-inflam-
matory effects of ATL, BV-2 cells were treated with an
ALX antagonist, Boc-2 (100 μM, 30 min) prior to treat-
ment with ATL. Pretreatment with Boc-2 inhibited
these effects in response to ATL (Figure 2).
To exclude the possibility that the decrease in the NO
and cytokines levels was simply due to the cytotoxicity
of the drug, cell viability was evaluated. The cytotoxic
effects of ATL in BV-2 cells were evaluated in the
absence or presence of LPS using MTT assays. ATL (1,
10 and 100 nM) and vehicle did not affect cell viability
(Figure 2D). When cells were treated with 100 ng/ml
LPS only, a decrease in viability was detected compared
with the control cells. However, cells pretreated with
ATL for 30 min showed no significant increase com-
pared with cells that were treated with LPS only (Figure
2D). Therefore, the inhibitory effect of ATL on LPS-
induced, inflammation-related responses in activated
BV-2 cells was not the result of ATL effects on cell
survival.
Figure 1 ALX expression in murine BV-2 microglial cells. BV-2
cells were incubated with or without LPS (100 ng/ml) at 37°C for 6
h. Total RNA was extracted and the expressions of ALX1/FPR-rs1 and
ALX2/FPR2 mRNAs were examined by RT-PCR. b-Actin was used as
a loading control. RT-PCR products were electrophoresed on 2%
agarose gel. Quantification of ALX1/FPR-rs1 and ALX2/FPR2 mRNAs
levels was performed by densitometric analysis. Each value
represents the mean ± SEM for three independent experiments.
#P
<0.05 compared with control.
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To find out whether ATL suppresses iNOS, IL-1b and
TNF-a expression at the transcriptional level, BV-2 cells
were incubated for 30 min with the indicated concentra-
tions of ATL and then incubated with 100 ng/ml LPS
for 6 h. The relative amounts of iNOS, IL-1b and TNF-
a mRNA were determined by real-time RT-PCR. As
anticipated, LPS induced am a r k e di n c r e a s ei ni N O S ,
IL-1b and TNF-a mRNA in BV-2 cells, about 20, 11,
26-fold increase, respectively (Figure 3). Pretreatment
with ATL reduced LPS-induced up-regulation of iNOS,
IL-1b and TNF-a mRNA levels in a dose-dependent
manner (Figure 3). The inhibitory effects of ATL on
LPS-induced iNOS mRNA up-regulation were accompa-
nied by attenuation of iNOS protein induction (Figure
3B). ATL inhibition of LPS-induced expression of iNOS,
IL-1b and TNF-a was reversed after pre-exposure of
BV-2 cells to the ALX antagonist Boc-2 (100 μM) for 30
min (Figure 3). Taken together, our current data prove
that ATL inhibits the inflammatory activation of BV-2
microglia cells with respect to NO production and pro-
inflammatory cytokine expression.
ATL inhibits nuclear translocation of NF-B and
degradation of IB-a
Because ATL reduced the transcriptional activation of
iNOS, IL-1b and TNF-a genes, it is likely that it blocks
signaling events involved in transcriptional activation of
these genes. Expression of iNOS and cytokines genes
requires NF-B activation and nuclear translocation to
interact with DNA. Therefore, the involvement of NF-
B nuclear translocation in ATL-induced suppression of
NO and cytokines was examined by fluorescence micro-
scopy. LPS stimulation caused obvious translocation of
NF-B p65 from the cytoplasm into the nucleus 60 min
after activation (Figure 4A), whereas the presence of 100
nM ATL reduced this (Figure 4B). To further verify the
p65 nuclear translocation data, we analyzed the cells by
western blotting and found that pretreatment of cells
with 100 nM ATL prevented p65 nuclear localization
induced by LPS (Figure 4C and 4D).
To address the possibility that the impaired nuclear
translocation of p65 was due to inhibition of degrada-
tion of IB-a,w ee x a m i n e dt h ee f f e c to fA T Lo nI B-a
degradation induced by LPS. Western blot analysis
Figure 2 Inhibition of NO, IL-1b and TNF-a production by ATL in LPS-stimulated BV-2 cells. BV-2 cells were pretreated with vehicle
(0.035% ethanol) or various concentrations of ATL (1, 10 and 100 nM) for 30 min in the absence or presence of 100 μM Boc-2 (30 min before
ATL treatment), a lipoxin receptor antagonist, followed by stimulated with LPS (100 ng/ml) for 24 h. (A) Nitrite content was measured using the
Griess reaction. The concentration of IL-1b (B) and TNF-a (C) in culture media was measured using a commercial ELISA kit. (D) Cell viability was
assessed by MTT assay, and the results are expressed as the percentage of surviving cells compared to control cells. Each value represents the
mean ± SEM for three independent experiments. **P <0.01 compared with LPS in the absence of ATL;
##P< 0.01 compared with vehicle.
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nificantly reversed by 100 nM ATL in BV-2 cells (Figure
4E).
ATL inhibits LPS-induced ERK and p38 MAPK activation
Along with NF-B, MAPKs are known to play an
important role in the signaling pathways that induce
proinfiammatory cytokines and iNOS in glial cells [28].
To investigate whether the inhibition of infiammation
by ATL is regulated by the MAPK pathway, we exam-
ined the effects of ATL on LPS-induced phosphoryla-
tion of ERK, p38 MAPK and JNK in BV-2 microglia by
western blot analysis. Cells were pretreated with 100
nM ATL for 30 min and then incubated with 100 ng/
ml LPS for 30 min. The 30-min treatment of LPS was
determined to be optimal in a preliminary study that
examined MAPK phosphorylation at 0, 10, 20, 30, and
60 min after LPS treatment (data not shown). ATL
(100 nM) markedly inhibited ERK and p38 MAPK acti-
vation, while phosphorylation of JNK was not affected
(Figure 5A-C). Strikingly, ATL could induce JNK phos-
phorylation without effect on ERK and p38 MAPK
activity.
ATL inhibits LPS-induced NF-B and AP-1 DNA binding
activity
To determine the effects of ATL on transcription fac-
tor signaling pathways that might mediate LPS-
induced proinfiammatory cytokines production, EMSA
was performed. BV-2 cells were pretreated with vehi-
cle and 100 nM ATL for 30 min before stimulation
with LPS (100 ng/ml) for 1 h. NF-B and AP-1 bind-
ing activities were induced by LPS treatment (Figure
6A and 6B, lane 3). Binding specificity was verified by
incubating nuclear extracts from LPS-stimulated BV-2
cells with excess unlabeled specific competitor oligo-
nucleotide probe (Figure 6A and 6B, lane 5). Pretreat-
ment with ATL markedly reduced the LPS-induced
DNA-binding activity of NF-Ba n dA P - 1( F i g u r e6 A
and 6B, lane 4).
Figure 3 Inhibition of iNOS, IL-1b and TNF-a mRNA expression by ATL in LPS-stimulated BV-2 cells. BV-2 cells were pretreated with ATL
(1, 10 and 100 nM) for 30 min in the absence or presence of 100 μM Boc-2 (30 min before ATL treatment) followed by incubation with LPS
(100 ng/ml). Total RNA was prepared 6 h later and expression of iNOS (A), IL-1b (C) and TNF-a (D) mRNA was measured by real-time PCR. Levels
of each mRNA were normalized to those of the house-keeping gene b-actin. The expression of iNOS protein was assessed by western blot
analysis 24 h later (B). Detection of b-actin was also carried out to confirm the equal loading of proteins. Each value represents the mean ± SEM
for three independent experiments.*P < 0.05 compared with LPS in the absence of ATL;**P <0.01 compared with LPS in the absence of ATL;
##P
< 0.01 compared with vehicle.
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microglial cells. (A) BV-2 cells were stimulated with 100 ng/ml LPS for the indicated times. Subcellular localization of p65 subunit was evaluated
using an anti-p65 antibody and a FITC-labelled anti-rabbit IgG antibody. DNA was stained using DAPI to visualize nuclei, and cells were
visualized using laser confocal scanning microscopy. Note that nuclear translocation of the p65 subunit is not complete, but that part of the
cytoplasmic p65 is translocated to the nucleus so that the distinction between the nucleus and the cytoplasm blurs. This is obvious 60 min after
activation. (B) BV-2 cells were stimulated with 100 ng/ml LPS in the absence or presence of 100 nM ATL that had been added 30 min before
activation. Subcellular location of the p65 subunit was tested using immunofluorescence assay 60 min after activation. (C) BV-2 cells were
stimulated as in B. Cytoplasmic and nuclear extracts were separated by SDS-PAGE and immunoblotted with anti-p65 antibody. The same extracts
were re-electrophoresed and immunoblotted for b-actin or lamin B to monitor loading. A representative result from three independent
experiments is shown. (D) Quantification of cytoplasmic and nuclear p65 bands from the experiments in C was normalized by b-actin or lamin B.
(E) BV-2 cells were pretreated with vehicle or 100 nM ATL for 30 min and stimulated with LPS (100 ng/ml). Levels of IB-a in cellular lysates
were analyzed using western blotting at indicated times. Quantification of IB-a protein levels was performed by densitometric analysis. Data are
presented as mean ± SEM for three independent experiments.*P < 0.05 compared with LPS in the absence of ATL;**P <0.01 compared with LPS
in the absence of ATL;
##P < 0.01 compared with vehicle.
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Our present data provide the first evidence that ATL
inhibits the infiammatory activation of microglia. To
date, two separate LXA4 receptors (ALX1/FPR-rs1 and
ALX2/FPR2) have been identified in mice [15,29].
Mouse ALX2/FPR2 is expressed by neutrophils, mono-
cytes, macrophages, dendritic cells, and microglial cells,
and its transcripts are detected at high levels in spleen
and lung [30]. ALX1/FPR-rs1a n dA L X 2 / F P R 2a r eb o t h
expressed in the mouse pituitary gland, hypothalamic
tissue and vomeronasal organ [31,32]. As demonstrated
by RT-PCR analysis, ALX1/FPR-rs1 and ALX2/FPR2 are
both expressed in BV-2 microglial cells. ATL reduced
LPS-induced production of NO, IL-1b and TNF-a in
BV-2 microglial cells. This is a receptor-mediated effect
as it disappeared when microglial cells were pretreated
with Boc-2 before ATL treatment. Quantitative PCR
analysis showed that ATL markedly suppresses iNOS,
IL-1b and TNF-a gene expression in BV-2 microglia
cells. Similarly, this effect was abrogated by the use of
Boc-2. NF-B, ERK and p38 MAPK pathways are at
least partly involved in the anti-infiammatory mechan-
isms of ATL in BV-2 cells. Thus, ATL is a promising
agent for preventing and treating neuroinflammation
and may be useful for mitigating a dysregulated linkage
between the immune system and brain.
Although microglial activation has important repaira-
tive functions in the CNS, microglial cell activation in
infection, infiammation, or injury may go beyond con-
trol and eventually produce detrimental effects that
override the beneficial effects. Activation of microglia
leads to release of various toxic molecules such as
superoxide, NO, IL-1b and TNF-a, contributing to neu-
ronal damage in various neurodegenerative disorders [1].
LX possesses dual anti-inflammatory and pro-resolu-
tion activities that have been demonstrated in a multi-
tude of acute and chronic inflammatory conditions [11].
Previously, LXA4, ATL and their stable analogues have
Figure 5 Inhibition of LPS-induced phosphorylation of ERK and p38 MAPK in BV-2 microglial cells. BV-2 cells were stimulated with 100
ng/ml LPS in the absence or presence of 100 nM ATL that had been added 30 min before activation. Levels of ERK and phosphorylated ERK (A),
p38 and phosphorylated p38 (B), and JNK and phosphorylated JNK (C) were analyzed using western blotting 30 min after stimulation with LPS.
The figures show representative results of three independent experiments. Each bar represents the means ± SEM. **P < 0.01 compared with LPS
in the absence of ATL;
#P< 0.05 compared with vehicle;
##P < 0.01 compared with vehicle.
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properties of the central nervous system, such as neural
stem cell proliferation and differentiation, pain, and cer-
ebral ischemia [17-19,33]. In primary murine microglia
or N9 microglial cells, expression of ALX2/FPR2 has
been identified and is up-regulated by inflammatory sti-
muli [20,21]. In the present study, the expression of
ALX2/FPR2 and another murine high-affinity ALX1/
FPR-rs1 were confirmed in BV-2 microglial cells. These
findings suggest that ATL could work as a modulator of
the inflammatory reaction of the brain immune system,
eventually acting as a microglial activation repressor.
NO and pro-infiammatory cytokines such as IL-1b
and TNF-a are known to be important mediators in the
process of infiammation. These proinfiammatory media-
tors are thought to be responsible for some of the harm-
ful effects of brain injuries and diseases, including
ischemia, Alzheimer’sd i s e a s e ,P a r k i n s o n ’s disease and
multiple sclerosis [34]. Under various pathological con-
ditions associated with infiammation, large amounts of
NO are produced in the brain as a result of the induced
expression of iNOS in glial cells [35]. High levels of NO
exert their toxic effects through multiple mechanisms,
including lipid peroxidation, mitochondrial damage,
protein nitration and oxidation, depletion of antioxidant
reserves, activation or inhibition of various signaling
pathways, and DNA damage [35]. Therefore, the effect
of ATL on NO production and iNOS expression in
LPS-stimulated microglia cells was examined. As shown
in previous research [36,37], NO is produced at low
levels in unstimulated microglia. Stimulation of BV-2
microglial cells with LPS induced strong NO production
and iNOS expression. The magnitude of the NO/iNOS
response to LPS in BV-2 microglial cells is different in
different studies with different concentrations as well as
durations of LPS treatment. In the present study, ATL
markedly reduced NO production and mRNA and pro-
tein expression of iNOS in dose-dependent manners
without significant cytotoxicity. This indicates that inhi-
bition of NO production by ATL is a result of inhibition
of iNOS gene expression. Previous studies also have
shown that LXA4 and ATL analogues inhibit LPS-
induced NO production and peroxynitrite formation in
human leukocytes [38] and in mouse lung [39].
Pro-infiammatory cytokines produced by activated
microglia, including IL-1b and TNF-a, play an impor-
tant role in the process of neuroinfiammatory diseases
[34]. IL-1b is a potent pro-infiammatory cytokine that
Figure 6 Inhibitory effects of ATL on NF-B and AP-1 DNA-binding activities. BV-2 cells were pretreated with ATL for 30 min and
stimulated with LPS for 1 h. Nuclear extracts were prepared and used to analyze NF-B (A) and AP-1 (B) DNA-binding activity by EMSA, as
described in Methods. Binding specificity was confirmed by unlabelled probe (100-fold in excess; lane 5) to compete with labelled
oligonucleotide. The arrow indicates the NF-B or AP-1 binding complex. Free-labelled probes are also indicated by an arrow. Results were
confirmed by three independent experiments.
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Page 9 of 12acts through IL-1 receptors found on numerous cell
types, including neurons and microglia. TNF-a can
cause cell death directly by binding to neuronal TNF
receptors linked to death domains that activate caspase-
dependent apoptosis [40] or by potentiating glutamate
release, thereby enhancing excitotoxicity [41]. IL-1b and
TNF-a also drive self-propagating cycles of microglial
activation and neuroinflammation by inducing activation
of NF-B, cytokine generation and further activation of
NF-B. Thus, inhibition of cytokine production or func-
tion serves as a key mechanism in the control of neuro-
degeneration. Our results showed that ATL markedly
attenuates the production of IL-1b and TNF-a,a n d
their mRNA expressions; induced by LPS in BV-2 cells.
Consistent with our findings, similar results have shown
that LXA4 and ATL inhibit LPS-induced production of
IL-1b and TNF-a in uvea and in macrophages and
endothelial cells [42-44].
In subsequent studies, we found that ATL has a
strong inhibitory effect on infiammatory signaling path-
ways that include NF-B and MAPK/AP-1. NF-B
activity increases in acute neurodegenerative disorders
such as stroke, severe epileptic seizures, and traumatic
brain injury; and in chronic neurodegenerative condi-
tions, including Alzheimer’s disease, Parkinson’s disease,
Huntington disease, and amyotrophic lateral sclerosis
[45]. In general, activation of NF-B in microglia contri-
butes to neuronal injury and promotes the development
of neurodegenerative disorders [45]. NF-Bi sk n o w na s
a pleiotropic regulator of various genes involved in the
production of many proinfiammatory cytokines and
enzymes. NF-B is also a central regulator of microglial
responses to activating stimuli, including LPS and cyto-
kines [46]. In this study, ATL was able to inhibit the
LPS-evoked degradation of IB-a, nuclear translocation
of NF-B p65 and the DNA-binding activities of NF-B
in BV-2 cells. Previous studies have shown that LXs
reduce nuclear translocation of NF-B in human neu-
trophils, mononuclear leukocytes [38] and macrophages
[43]. It has also been reported that ATLs reduce NF-
B-mediated transcriptional activation in an ALX-
dependent manner, and inhibit the degradation of IB
[47]. Therefore, induction of anti-inflammatory
r e s p o n s e sb yL X sm a yb ed e p e n d e n to nt h eN F - Bs i g -
naling pathway.
In addition, LPS also activates MAPK pathways which
lead to the induction of another transcription factor,
AP-1. MAPKs are a group of signaling molecules that
appear to play key roles in infiammatory processes [48].
We found that phosphorylation of ERK and p38 MAPK
in response to LPS is decreased by ATL treatment. Our
results also show that ATL treatment of BV-2 microglia
results in decreased DNA-binding activities of AP-1 fol-
lowing LPS stimulation. This observation is in line with
studies in mesangial cells, endothelial cells, neutrophils,
fibroblasts and T cells, which have shown that ERK
and/or p38 MAPK activation is attenuated in the pre-
sence of LXs [42,49-51]. In the present study, ATL
failed to inhibit LPS-induced phosphorylation of JNK. A
previous study in primary astrocytes found that an ATL
analogue prevents ATP-evoked JNK phosphorylation,
but has no effect on TNF-a-induced JNK phosphoryla-
tion [33]. Strikingly, our results show that ATL induces
JNK phosphorylation, but has no effect on ERK and p38
MAPK activity. In another study, LXA4 attenuated
microvascular fluid leaks caused by LPS partly mediated
by the JNK signaling pathway [52]. LXA4 and ATL ana-
logues could promote ERK phosphorylation in macro-
phages and monocytes [53,54]. The reasons for these
discrepancies are mainly due to differences in experi-
mental models, cell types and stimulators.
Conclusions
In summary, our results show that ATL inhibits release
of NO and pro-inflammatory cytokines in a concentra-
tion-dependent manner. Moreover, ATL acts at the level
of transcription in LPS-stimulated microglia. A possible
mechanism for this effect involves ATL’s ability to acti-
vate a signaling cascade that results in repression of NF-
B, ERK and p38 MAPK activation in activated micro-
glia. Given the fact that microglial activation contributes
to the pathogenesis of neurodegenerative diseases, ATL
may be considered as a potential therapeutic agent for
neurodegenerative diseases involving
neuroinflammation.
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